Rep. Eliot Engel (D-NY) made a brief appearance Tuesday at a Congressional briefing, hosted by several TB advocacy organizations, highlighting tuberculosis and its continuation as a global health threat. He called the fact that TB hasn’t been eradicated “a sin,” and then briefly announced the newly formed U.S. House of Representatives TB Elimination Caucus – […]
Otsuka Pharmaceuticals is the top private funder of tuberculosis (TB) research and drug development in the world. Last year, Otsuka established a Geneva-based subsidiary – Otsuka SA – to serve as “the company’s central operations for developing and implementing public health policies and corporate social responsibility programs in connection with its global TB program,” according to the company’s website.
As part of our reporting in advance of World TB Day on Saturday (March 24), Science Speaks interviewed Patrizia Carlevaro, PhD, the leader of Otsuka SA, to discuss Otsuka’s latest research to address drug-resistant forms of TB, the world’s emerging tuberculosis “hotspots,” and other efforts by the subsidiary organization to tackle TB.
HIV
As the federal Ending the HIV epidemic takes form, experts talk details, challenges: “How do we get there from here?” WASHINGTON, DC – Nearly four decades […]
Tuberculosis
Patients treated for multidrug-resistant tuberculosis with an experimental regimen containing a repurposed drug for a year had similar rates of successful outcomes as patients treated with […]
Research & Development
While a World Health Organization-led strategy aims to provide 1.4 billion doses of vaccine against yellow fever to achieve 80% vaccination coverage across countries by 2026 […]
Policy
The following is a guest post By Sharon Weir, Ph.D. of MEASURE Evaluation The Priorities for Local AIDS Control Efforts — PLACE –method aims to improve […]